Abstract
Significant aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) has been shown to be associated with worse mid-term outcome. The two-year follow-up results of the PARTNER US trial showed that not only ≥3/4 AR grade, but also grade 2 had a significant impact on mortality. Thus, prevention and treatment of significant AR after TAVI is of great importance. Usually, AR after TAVI consists mostly of paravalvular leak and significant central AR is uncommon. Here we describe measures to decrease the risk of AR after TAVI which are currently available.
| Original language | English |
|---|---|
| Journal | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology |
| Volume | 8 Suppl Q |
| Publication status | Published - 2012 Sep |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Treatment and prevention of aortic regurgitation after transcatheter aortic valve implantation. / Hayashida, Kentaro; Lefèvre, Thierry.
In: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 8 Suppl Q, 09.2012.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment and prevention of aortic regurgitation after transcatheter aortic valve implantation.
AU - Hayashida, Kentaro
AU - Lefèvre, Thierry
PY - 2012/9
Y1 - 2012/9
N2 - Significant aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) has been shown to be associated with worse mid-term outcome. The two-year follow-up results of the PARTNER US trial showed that not only ≥3/4 AR grade, but also grade 2 had a significant impact on mortality. Thus, prevention and treatment of significant AR after TAVI is of great importance. Usually, AR after TAVI consists mostly of paravalvular leak and significant central AR is uncommon. Here we describe measures to decrease the risk of AR after TAVI which are currently available.
AB - Significant aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) has been shown to be associated with worse mid-term outcome. The two-year follow-up results of the PARTNER US trial showed that not only ≥3/4 AR grade, but also grade 2 had a significant impact on mortality. Thus, prevention and treatment of significant AR after TAVI is of great importance. Usually, AR after TAVI consists mostly of paravalvular leak and significant central AR is uncommon. Here we describe measures to decrease the risk of AR after TAVI which are currently available.
UR - http://www.scopus.com/inward/record.url?scp=84894368966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894368966&partnerID=8YFLogxK
M3 - Article
C2 - 22995110
AN - SCOPUS:84894368966
VL - 8 Suppl Q
JO - EuroIntervention
JF - EuroIntervention
SN - 1774-024X
ER -